Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology
+$0.01 today
- Market cap
- $113.54M
- Beta
- 0.25
- P/E (TTM)
- -13.3
- EPS (TTM)
- -$0.08
Volume 7.09M
Average 4.03M
AKBA Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Akebia Therapeutics, Inc.NASDAQ: AKBA
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses remains negative
Q1 FY2026 other income / expenses was -$4.23M, compared with -$7.4M a year earlier. Trailing-twelve-month other income / expenses was -$24.05M.
Context
- Other income / expenses amounted to 11.5% of revenue in FY2025, down 0.3 pp from a year earlier.
- Other income / expenses grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other income / expenses holds near -$4.23M or moves back toward the trailing-twelve-month quarterly average of -$6.01M.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- (27.22M) USD
- Year-over-year change
- -43.7%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (27.22M) | -43.7% |
| FY2024 | 2024-12-31 | (18.94M) | -234.1% |
| FY2023 | 2023-12-31 | (5.67M) | +57.8% |
| FY2022 | 2022-12-31 | (13.45M) | +23.3% |
| FY2021 | 2021-12-31 | (17.52M) | — |
Other Income / Expenses vs competitors
How AKBA compares with its peers on the latest reported figures
- AKBA's LTM Mar 2026 other income / expenses of -$24.05M is the lowest of the 10 companies compared; the peer median is $7M.
- Its year-over-year change of -3.3% is the 6th highest of 9, against a peer median of +12.9%.
- Other income / expenses amounts to 10.3% of revenue for AKBA, versus a peer median of 12.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $182.15M | +5325.1% | +79.3% | 148.9% | |
| LTM Mar 2026 | $20.28M | -10.8% | — | 35.0% | |
| LTM Mar 2026 | $18.65M | -30.6% | +97.1% | 21.1% | |
| LTM Mar 2026 | $16.66M | +19.9% | +94.7% | — | |
| LTM Mar 2026 | $7M | +6.0% | +37.7% | — | |
| LTM Mar 2026 | $3.76M | +136.9% | — | — | |
| LTM Dec 2025 | -$1.21M | — | — | 1.0% | |
| LTM Mar 2026 | -$1.7M | -138.4% | — | 3.1% | |
| LTM Mar 2026 | -$2.61M | +55.1% | — | 0.9% | |
| LTM Mar 2026 | -$24.05M | -3.3% | — | 10.3% | |
| Peer median (excluding AKBA) | $7M | +12.9% | +87.0% | 12.1% | |
Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 211.65M | 292.48M | 194.62M | 160.18M | 236.2M |
| Cost of Revenue | 81.49M | 22.5M | 74.15M | 63.18M | 39.46M |
| Gross Profit | 130.16M | 269.99M | 120.47M | 97M | 196.73M |
| Gross Margin | 61.5% | 92.3% | 61.9% | 60.6% | 83.3% |
| Research & Development | 147.85M | 165.99M | 63.08M | 37.65M | 62.36M |
| Selling, General & Admin | 174.14M | 138.6M | 100.23M | 106.55M | 107.48M |
| Operating Expenses | 394.66M | 350.77M | 166.73M | 147.48M | 173.24M |
| Depreciation & Amortization | 37.97M | 37.7M | 37.63M | 37.5M | 1.27M |
| EBITDA | (189.91M) | 3.06M | (8.27M) | (13.72M) | 21.73M |
| EBITDA Margin | -89.7% | 1.0% | -4.2% | -8.6% | 9.2% |
| Operating Income | (264.5M) | (80.78M) | (46.26M) | (50.47M) | 23.5M |
| Operating Margin | -125.0% | -27.6% | -23.8% | -31.5% | 9.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 19.94M | 15.69M | 6.03M | 18.19M | 24.18M |
| Other Income / Expenses | (17.52M) | (13.45M) | (5.67M) | (18.94M) | (27.22M) |
| Income Before Tax | (282.02M) | (94.23M) | (51.93M) | (69.41M) | (3.72M) |
| Pre-Tax Margin | -133.3% | -32.2% | -26.7% | -43.3% | -1.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.62M |
| Net Income | (282.02M) | (94.23M) | (51.93M) | (69.41M) | (5.35M) |
| Net Margin | -133.3% | -32.2% | -26.7% | -43.3% | -2.3% |
| EPS (Basic) | (1.48) | (0.58) | (0.28) | (0.33) | (0.02) |
| EPS (Diluted) | (1.48) | (0.58) | (0.28) | (0.33) | (0.02) |
| Weighted Avg Shares | 165.95M | 182.78M | 187.47M | 210.95M | 257.16M |
| Weighted Avg Shares (Diluted) | 165.95M | 182.78M | 187.47M | 210.95M | 257.16M |
Akebia Therapeutics, Inc.
NASDAQ:AKBA
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.